CSL Limited (ASX:CSL) has agreed to exercise its right for acquiring a clinical-stage biotechnology company Vitaeris Inc, that is focused on phase 3 development of a treatment for rejection in solid organ kidney transplant recipients.
With this acquisition, Vitaeris research assets join CSL964 and CSL842 as part of CSL’s product portfolio in late-stage development for treatment of significant unmet medical needs in the community of transplantation. Moreover, the cost of acquisition is modest, and it does not materially alter CSL’s profit anticipation for the fiscal year 2020.
CSL quoted $ 278.17 at 12.28 PM AEST on 9 June 2020.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.